SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
Belzutifan/lenvatinib also showed a favorable trend towards improvement for overall survival in this advanced renal cell carcinoma population.
Clinical Implications Remain After Dasatinib CRL in CML/ALL
The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.
Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report
Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.
How Can Lower-Income Countries Maintain Representation in Clinical Trials?
Lower- and middle-income countries must work to build trust with pharmaceutical companies to enhance representation in cancer-related clinical trials.
What Path to Approval Has Dasatinib Taken in CML/ALL?
Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.
Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care
Adam Friedman, MD, FAAD, discusses systemic barriers to timely dermatologic consultation for patients with cancer.
ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC
Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.
FDA Approves Revumenib in R/R NPM1-Mutant AML
Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.
FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma
For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.
Enhancing Radiotherapy Approaches Across Community Oncology Settings
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
The evaluation of MT-125’s safety and preliminary activity in glioblastoma is underway in a phase 1/2 trial.
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
Belantamab mafodotin has been approved for multiple myeloma despite the FDA’s ODAC committee voting against the treatment due to ocular toxicities.
FDA Accepts NDA for New Nilotinib Formulation in CML
The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.
Crucial Communication Strategies for Dermatologic AEs of Cancer Therapies
Adam Friedman, MD, FAAD, discusses essential communication strategies for oncologists to address patient fears about dermatologic adverse effects.
Collagen Implant May Improve Local Control of Metastatic Brain Tumors
Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
Investigators are currently assessing the antibody drug conjugate HDP-101 as part of a phase 1/2a study.
Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC
Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.